Skip to main content

Kyntra Bio, Inc.

corporate_fare Company Profile

Kyntra Bio, Inc.

KYNB·NASDAQ·Life Sciences·CIK 0000921299

Kyntra Bio, Inc. is a biopharmaceutical company focused on developing new treatments for cancer and anemia. The company rebranded from "FibroGen, Inc." to "Kyntra Bio, Inc." in January 2026, with its common stock trading under the Nasdaq symbol "KYNB" starting January 8, 2026. Kyntra Bio is developing FG-3246, an antibody-drug conjugate targeting CD46, for metastatic castration-resistant prostate cancer (mCRPC) and other cancers. This program also includes FG-3180, a CD46-targeted PET biomarker and imaging agent. A Phase 2 monotherapy dose optimization study for FG-3246 in mCRPC, with an exploratory sub-study of FG-3180, began in the third quarter of 2025. Kyntra Bio and its partners developed roxadustat (爱瑞卓 ® , EVRENZO TM ), which is approved in Europe, Japan, the People's Republic of China (China), and other countries for treating anemia in chronic kidney disease (CKD) patients, both on and not on dialysis. On August 29, 2025, Kyntra Bio sold its China operations, including FibroGen International (Hong Kong) Ltd. and its subsidiary FibroGen (China) Medical Technology Development Co., Ltd., along with its 51.1% interest in Beijing Falikang Pharmaceutical Co. Ltd., to AstraZeneca Treasury Limited for $220.4 million. This consideration included $85.0 million in enterprise value and $135.4 million in net cash held in China. AstraZeneca AB was the commercialization partner for roxadustat in greater China. Kyntra Bio retains roxadustat rights in the U.S., Canada, Mexico, and all markets not held by AstraZeneca or licensed to Astellas Pharma Inc.

Kyntra Bio, Inc. (NASDAQ:KYNB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for KYNB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 8/10. Across its 17 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for KYNB spans 10-Q, 8-K, 10-K.

Recent high-impact activity:

  • Kyntra Bio 10-Q: $44.1M Cash Into 2028, FG-3246 Killed, NovaQuest Cap Cut to $15M
  • Kyntra Bio Posts $0.04 Q3 EPS, Kills FG-3246, Ties Phase 3 to New Financing
  • Kyntra Bio Scraps FG-3246 Phase 2 Trial, Posts $0.2M Q3 Profit
  • Nasdaq Moves to Delist Kyntra Bio; Company Seeks Hearing to Stay Suspension
  • Kyntra Bio Slashes Royalty Financing Obligation by $60M with $42.6M Upfront Payment

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$6.44M
Net Income
$183.45M
Diluted EPS
$45.37
Op. Cash Flow
-$4.77M
Free Cash Flow
-$4.81M
Gross Profit
$5.88M
Operating Income
-$45.9M
Cash & Equivalents
$47.87M
Debt / Equity
0.00×
Net Margin
28.49×
Shares Outstanding
4.05M sh
Source: 10-K · filed 2026-03-16 · accession 0001193125-26-108346

Short Interest & Short Volume

4.68 days to cover

FINRA reported short interest of 95,811 shares in KYNB as of the October 30, 2026 settlement, a 0.9% increase from the prior period — about 4.7 days to cover at its recent average daily volume. On November 20, 2026, 34.3% of KYNB volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)95,811 shares as of October 30, 2026
Change vs prior period▲ 0.9%
Days to cover4.68 at avg daily volume of 20,459
Daily short volume (FINRA facilities)34.3% of 25,281 shares on November 20, 2026
5-day average short volume50.2%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with K →
$1.8 -1.64% today
52-week range · as of 2026-11-16 $1.8 – $10.47
Market cap
$6.32M
Volume
37.4K (1.1× avg)
3-mo avg 35.4K
Live data · 2026-11-22 12:40 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed KYNB - Latest Insights

KYNB
Nov 16, 2026, 4:10 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.00
Real-time Price: $1.80 info
Change: -$1.20 (-40%) info
Market Cap: $6.318M info
KYNB
Nov 16, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.20
Real-time Price: $1.80 info
Change: -$1.40 (-44%) info
Market Cap: $6.318M info
KYNB
Nov 16, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.20
Real-time Price: $1.80 info
Change: -$1.40 (-44%) info
Market Cap: $6.318M info
KYNB
Oct 06, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $5.96
Real-time Price: $1.80 info
Change: -$4.16 (-70%) info
Market Cap: $6.318M info
KYNB
Aug 31, 2026, 5:18 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $7.65
Real-time Price: $1.80 info
Change: -$5.85 (-76%) info
Market Cap: $6.318M info
KYNB
Aug 31, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $7.65
Real-time Price: $1.80 info
Change: -$5.85 (-76%) info
Market Cap: $6.318M info
KYNB
Aug 13, 2026, 4:10 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $6.95
Real-time Price: $1.80 info
Change: -$5.15 (-74%) info
Market Cap: $6.318M info
KYNB
Aug 13, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.95
Real-time Price: $1.80 info
Change: -$5.15 (-74%) info
Market Cap: $6.318M info
KYNB
Jun 11, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $7.05
Real-time Price: $1.80 info
Change: -$5.25 (-74%) info
Market Cap: $6.318M info
KYNB
Jun 09, 2026, 5:04 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.69
Real-time Price: $1.80 info
Change: -$4.89 (-73%) info
Market Cap: $6.318M info
KYNB
May 12, 2026, 4:05 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $7.23
Real-time Price: $1.80 info
Change: -$5.43 (-75%) info
Market Cap: $6.318M info
KYNB
May 11, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.85
Real-time Price: $1.80 info
Change: -$5.05 (-74%) info
Market Cap: $6.318M info
KYNB
May 11, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $6.85
Real-time Price: $1.80 info
Change: -$5.05 (-74%) info
Market Cap: $6.318M info
KYNB
May 08, 2026, 4:49 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $6.95
Real-time Price: $1.80 info
Change: -$5.15 (-74%) info
Market Cap: $6.318M info
KYNB
Apr 09, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $7.18
Real-time Price: $1.80 info
Change: -$5.38 (-75%) info
Market Cap: $6.318M info
KYNB
Mar 16, 2026, 4:10 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $7.27
Real-time Price: $1.80 info
Change: -$5.47 (-75%) info
Market Cap: $6.318M info
KYNB
Mar 16, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $6.82
Real-time Price: $1.80 info
Change: -$5.02 (-74%) info
Market Cap: $6.318M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets